AtaiBeckley (ATAI) EBT Margin (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly EBT Margin of 3121.8% for Q1 2026, down 142991.0% year-over-year from N/an in Q1 2025, and down 84.51% quarter-over-quarter from 1691.9% in Q1 2025.
AtaiBeckley (ATAI) EBT Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has reported EBT Margin for 5 years, with the latest figure at 8139.79% in Q3 2025.
- Quarterly EBT Margin rose 5801771.0% year-over-year to 8139.79% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 5077.86% (up 3345417.0% YoY) and the FY2024 annual result came in at 48183.44%, down 3567198.0% from the prior year.
- EBT Margin for Q1 2026 stood at 3121.8%, down from 1691.9% in the prior quarter.
- The five-year high for EBT Margin was 1691.9% in Q1 2025, with the low at 3121.8% in Q1 2026.
- A 5-year average of 54835.77% and a median of 19656.57% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin jumped 18845718 bps in 2023, then plunged 22475556 bps in 2024.
- Over 5 years, EBT Margin stood at 21121.3% in 2021, then sank by 390 bps to 103476.32% in 2022, then climbed by 2 bps to 101777.78% in 2023, then slumped by 221 bps to 326533.33% in 2024, then jumped by 98 bps to 8139.79% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 8139.79%, 3846.04%, and 1691.9% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -8,139.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,906.34% |
| Mar 31, 2026 | -3,121.80% |
| Sep 30, 2025 | -8,139.79% |
| Jun 30, 2025 | -3,846.04% |
| Mar 31, 2025 | -1,691.90% |
| Mar 31, 2025 | -1,691.90% |
| Dec 31, 2024 | -326,533.33% |
| Sep 30, 2024 | -66,157.50% |
| Jun 30, 2024 | -20,907.33% |
| Dec 31, 2023 | -101,777.78% |
| Sep 30, 2023 | 50,398.85% |
| Jun 30, 2023 | -18,405.81% |
| Mar 31, 2023 | -89,610.81% |
| Dec 31, 2022 | -103,476.32% |
| Sep 30, 2022 | -138,058.33% |
| Jun 30, 2022 | -18,121.18% |
| Dec 31, 2021 | -21,121.30% |
| Sep 30, 2021 | -9,952.63% |
| Mar 31, 2021 | 28.94% |